Karo Pharma resolves on sale of own shares
Under the the authorization from the 2021 Annual General Meeting, the Board of Directors has resolved to sell up to 1,768,000 own shares to expand the company’s financial flexibility. The sale of own shares shall be effected – on one or several occasions before the 2022 Annual General Meeting, where a new mandate should be requested if necessary – on Nasdaq Stockholm at a price within the effective registered price interval on Nasdaq Stockholm, such interval being the interval between the highest purchase price and the lowest sales price. The transfers shall be executed in accordance with